Global Gammaretroviral Vector Market Key Players Competitive Survey Report 2023
The global Gammaretroviral Vector market size in 2022 is XX million US dollars, and it is expected to be XX million US dollars by 2029, with a compound annual growth rate of 17.70% expected in 2023-2029.
MARKET COMPETITIVE LANDSCAPE:
The main players in the Gammaretroviral Vector market include Novasep (France), MerckKGaA (Germany), Charles River Laboratories (U.K.), uniQure N.V. (Netherlands), and Waisman Biomanufacturing (U.S.). The share of the top 3 players in the Gammaretroviral Vector market is XX%.
REGION SHARE:
The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and North America accounted for XX%, Europe accounted for XX% of Gammaretroviral Vector market, and Asia Pacific accounted for XX%.
SEGMENT OVERVIEW:
The report segments the market by Type and Application. Lentiviral Vectors accounted for XX% of Gammaretroviral Vector market in 2022. Adenoviral Vectors share of XX%.
Gene Therapy accounted for XX% of the Gammaretroviral Vector market in 2022. Vaccinology accounts for XX%.
Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
COVID-19 Impact:
Outbreak of COVID-19 pandemic due to lockdown restrictions imposed by governments around the world has affected the growth of the global Gammaretroviral Vector market in 2020. The containment measures taken by the governments of various countries in response to control the outbreak of COVID-19 disrupted the entire supply chain by creating logistical interruptions, transportation restrictions, and product supply across borders.
The report analyzes the key trends in each segment of the global Gammaretroviral Vector market along with global and country-level forecasts from 2023 to 2028. Our report segments the market based on types and applications, thereby providing a detailed analysis of the market to help gain an in-depth understanding of the market and enable market participants, stakeholders, investors, etc. to have a clearer understanding of the market and judgment.
Key benefits to stakeholders:
The report provides a comprehensive quantitative analysis of various segments, historical and current market trends, market forecasts, and dynamics of the Gammaretroviral Vector market for 2017-2028.
The research report provides the latest information on the market drivers, challenges and opportunities of the global Gammaretroviral Vector market.
The study profiles the leading as well as the fastest growing regional markets. It further enables stakeholders to identify key country-level markets within each region.
Porter's Five Forces Analysis helps stakeholders assess the impact of new entrants, competitors, supplier strength, buyer strength, and threat of substitution. It helps stakeholders analyze the level of competition in the Gammaretroviral Vector industry and its attractiveness.
The competitive landscape enables stakeholders to understand their competitive environment and gain insight into the current position of the key players in the market.
The life sciences industry grows and continues to advance, driving innovation and improving healthcare outcomes for individuals around the world.
Artificial Intelligence (AI) and Machine Learning (ML): AI and ML technologies are increasingly being employed in life sciences research and development. They aid in drug discovery, optimizing clinical trials, analyzing vast amounts of biological data, and identifying patterns that can lead to breakthroughs in understanding diseases and developing new therapies.
Digital Health Technologies: Digital health technologies have seen rapid growth, especially in areas like telemedicine, wearable devices, and mobile health applications. These technologies enable remote patient monitoring, facilitate better healthcare access, and empower individuals to manage their health more effectively.
Wearable Devices and Remote Monitoring: Wearable devices, such as smartwatches and fitness trackers, have become more sophisticated, enabling continuous monitoring of vital signs and health parameters. These devices offer opportunities for early detection of health issues and improved management of chronic conditions.
Highlights-Regions
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Spain
Nordic
Asia Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Egypt
South Africa
UAE
Turkey
Saudi Arabia
Player list
Novasep (France)
MerckKGaA (Germany)
Charles River Laboratories (U.K.)
uniQure N.V. (Netherlands)
Waisman Biomanufacturing (U.S.)
Creative-Biogene (U.S.)
Aldevron (U.S)
Addgene (U.S.)
Oxford Biomedica (U.K.)
Thermo Fisher Scientific Inc (U.S.)
Fujifilm Corporation (Japan)
Spark Therapeutics Inc. (U.S.)
ABL Inc. (U.S.)
Boehringer Ingelheim International GmbH. (Germany)
Brammer Bio (U.S.)
Creative Biogene (U.S.)
General Electric (U.S.)
Pfizer Inc. (U.S.)
Types list
Lentiviral Vectors
Adenoviral Vectors
Adeno-Associated Viral Vectors
Other
Application list
Gene Therapy
Vaccinology
Table of Content
1 Gammaretroviral Vector Market Introduction and Overview
1.1 Gammaretroviral Vector Definition
1.2 Research Purposes
1.3 Report Timeline
1.4 Economic Analysis of Global Regions
1.5 Inflation Analysis
1.6 The Impact of the Russian-Ukrainian War on the Market
1.7 Coronavirus Disease 2020 (COVID-19) Impact on Global
2 Global Gammaretroviral Vector Historical Market Analysis by Type
2.1 Market Size Analysis by Types
2.2 Global Gammaretroviral Vector Revenue and Market Share by Type
3 Global Gammaretroviral Vector Historical Market Analysis by Application
3.1 Market Size Analysis by Application
3.2 Global Gammaretroviral Vector Revenue Market Share by Application (2018-2023)
4 Global Market Growth Trends Analysis
4.1 Global Gammaretroviral Vector Market Size (2018-2023)
4.2 Gammaretroviral Vector Growth Trends Analysis by Regions
4.2.1 Gammaretroviral Vector Market Size by Regions: 2018 VS 2023 VS 2029
4.2.2 Gammaretroviral Vector Historic Revenue Market Size by Regions (2018-2023)
4.2.3 North America Gammaretroviral Vector Market Size (2018-2023)
4.2.4 Europe Gammaretroviral Vector Market Size (2018-2023)
4.2.5 Asia-Pacific Gammaretroviral Vector Market Size (2018-2023)
4.2.6 Latin America Gammaretroviral Vector Market Size (2018-2023)
4.2.7 Middle East & Africa Gammaretroviral Vector Market Size (2018-2023)
5 North America
5.1 North America Gammaretroviral Vector Revenue by Countries
5.1.1 North America Gammaretroviral Vector Revenue by Countries (2018-2023)
5.2 North America Gammaretroviral Vector Revenue by Types
5.3 North America Gammaretroviral Vector Revenue by Applications
5.4 United States
5.5 Canada
6 Asia Pacific
6.1 Asia Pacific Gammaretroviral Vector Revenue by Countries
6.1.1 Asia Pacific Gammaretroviral Vector Revenue by Countries (2018-2023)
6.2 Asia Pacific Gammaretroviral Vector Revenue by Types
6.3 Asia Pacific Gammaretroviral Vector Revenue by Applications
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Gammaretroviral Vector Revenue by Countries
7.1.1 Europe Gammaretroviral Vector Revenue by Countries (2018-2023)
7.2 Europe Gammaretroviral Vector Revenue by Types
7.3 Europe Gammaretroviral Vector Revenue by Applications
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Nordic
8 Latin America
8.1 Latin America Gammaretroviral Vector Revenue by Countries
8.1.1 Latin America Gammaretroviral Vector Revenue by Countries (2018-2023)
8.2 Latin America Gammaretroviral Vector Revenue by Types
8.3 Latin America Gammaretroviral Vector Revenue by Applications
8.4 Brazil
8.5 Argentina
8.6 Mexico
9 Middle East & Africa
9.1 Middle East & Africa Gammaretroviral Vector Revenue by Countries
9.1.1 Middle East & Africa Gammaretroviral Vector Revenue by Countries (2018-2023)
9.2 Middle East & Africa Gammaretroviral Vector Revenue by Types
9.3 Middle East & Africa Gammaretroviral Vector Revenue by Applications
9.4 Egypt
9.5 South Africa
9.6 UAE
9.7 Turkey
9.8 Saudi Arabia
10 Global Gammaretroviral Vector Market Competition, by Players
10.1 Global Gammaretroviral Vector Revenue and Market Share by Players
10.2 Market Concentration Rate
10.2.1 Top 3 Gammaretroviral Vector Players Market Share in 2022
10.2.2 Top 6 Gammaretroviral Vector Players Market Share in 2022
10.2.3 Market Competition Trend
10.3 Gammaretroviral Vector Players Head Office, Business Provided
10.4 Gammaretroviral Vector Mergers & Acquisitions
10.5 Gammaretroviral Vector New Entrants and Expansion Plans
11 Players Profiles11.1 Novasep (France)
11.1.1 Novasep (France) Company Profile
11.1.2 Gammaretroviral Vector Product Overview
11.1.3 Novasep (France) Gammaretroviral Vector Market Performance (2018-2023)
11.1.4 Novasep (France) Business Overview
11.1.5 Recent Developments and Plans
11.2 MerckKGaA (Germany)
11.2.1 MerckKGaA (Germany) Company Profile
11.2.2 Gammaretroviral Vector Product Overview
11.2.3 MerckKGaA (Germany) Gammaretroviral Vector Market Performance (2018-2023)
11.2.4 MerckKGaA (Germany) Business Overview
11.2.5 Recent Developments and Plans
11.3 Charles River Laboratories (U.K.)
11.3.1 Charles River Laboratories (U.K.) Company Profile
11.3.2 Gammaretroviral Vector Product Overview
11.3.3 Charles River Laboratories (U.K.) Gammaretroviral Vector Market Performance (2018-2023)
11.3.4 Charles River Laboratories (U.K.) Business Overview
11.3.5 Recent Developments and Plans
11.4 uniQure N.V. (Netherlands)
11.4.1 uniQure N.V. (Netherlands) Company Profile
11.4.2 Gammaretroviral Vector Product Overview
11.4.3 uniQure N.V. (Netherlands) Gammaretroviral Vector Market Performance (2018-2023)
11.4.4 uniQure N.V. (Netherlands) Business Overview
11.4.5 Recent Developments and Plans
11.5 Waisman Biomanufacturing (U.S.)
11.5.1 Waisman Biomanufacturing (U.S.) Company Profile
11.5.2 Gammaretroviral Vector Product Overview
11.5.3 Waisman Biomanufacturing (U.S.) Gammaretroviral Vector Market Performance (2018-2023)
11.5.4 Waisman Biomanufacturing (U.S.) Business Overview
11.5.5 Recent Developments and Plans
11.6 Creative-Biogene (U.S.)
11.6.1 Creative-Biogene (U.S.) Company Profile
11.6.2 Gammaretroviral Vector Product Overview
11.6.3 Creative-Biogene (U.S.) Gammaretroviral Vector Market Performance (2018-2023)
11.6.4 Creative-Biogene (U.S.) Business Overview
11.6.5 Recent Developments and Plans
11.7 Aldevron (U.S)
11.7.1 Aldevron (U.S) Company Profile
11.7.2 Gammaretroviral Vector Product Overview
11.7.3 Aldevron (U.S) Gammaretroviral Vector Market Performance (2018-2023)
11.7.4 Aldevron (U.S) Business Overview
11.7.5 Recent Developments and Plans
11.8 Addgene (U.S.)
11.8.1 Addgene (U.S.) Company Profile
11.8.2 Gammaretroviral Vector Product Overview
11.8.3 Addgene (U.S.) Gammaretroviral Vector Market Performance (2018-2023)
11.8.4 Addgene (U.S.) Business Overview
11.8.5 Recent Developments and Plans
11.9 Oxford Biomedica (U.K.)
11.9.1 Oxford Biomedica (U.K.) Company Profile
11.9.2 Gammaretroviral Vector Product Overview
11.9.3 Oxford Biomedica (U.K.) Gammaretroviral Vector Market Performance (2018-2023)
11.9.4 Oxford Biomedica (U.K.) Business Overview
11.9.5 Recent Developments and Plans
11.10 Thermo Fisher Scientific Inc (U.S.)
11.10.1 Thermo Fisher Scientific Inc (U.S.) Company Profile
11.10.2 Gammaretroviral Vector Product Overview
11.10.3 Thermo Fisher Scientific Inc (U.S.) Gammaretroviral Vector Market Performance (2018-2023)
11.10.4 Thermo Fisher Scientific Inc (U.S.) Business Overview
11.10.5 Recent Developments and Plans
11.11 Fujifilm Corporation (Japan)
11.11.1 Fujifilm Corporation (Japan) Company Profile
11.11.2 Gammaretroviral Vector Product Overview
11.11.3 Fujifilm Corporation (Japan) Gammaretroviral Vector Market Performance (2018-2023)
11.11.4 Fujifilm Corporation (Japan) Business Overview
11.11.5 Recent Developments and Plans
11.12 Spark Therapeutics Inc. (U.S.)
11.12.1 Spark Therapeutics Inc. (U.S.) Company Profile
11.12.2 Gammaretroviral Vector Product Overview
11.12.3 Spark Therapeutics Inc. (U.S.) Gammaretroviral Vector Market Performance (2018-2023)
11.12.4 Spark Therapeutics Inc. (U.S.) Business Overview
11.12.5 Recent Developments and Plans
11.13 ABL Inc. (U.S.)
11.13.1 ABL Inc. (U.S.) Company Profile
11.13.2 Gammaretroviral Vector Product Overview
11.13.3 ABL Inc. (U.S.) Gammaretroviral Vector Market Performance (2018-2023)
11.13.4 ABL Inc. (U.S.) Business Overview
11.13.5 Recent Developments and Plans
11.14 Boehringer Ingelheim International GmbH. (Germany)
11.14.1 Boehringer Ingelheim International GmbH. (Germany) Company Profile
11.14.2 Gammaretroviral Vector Product Overview
11.14.3 Boehringer Ingelheim International GmbH. (Germany) Gammaretroviral Vector Market Performance (2018-2023)
11.14.4 Boehringer Ingelheim International GmbH. (Germany) Business Overview
11.14.5 Recent Developments and Plans
11.15 Brammer Bio (U.S.)
11.15.1 Brammer Bio (U.S.) Company Profile
11.15.2 Gammaretroviral Vector Product Overview
11.15.3 Brammer Bio (U.S.) Gammaretroviral Vector Market Performance (2018-2023)
11.15.4 Brammer Bio (U.S.) Business Overview
11.15.5 Recent Developments and Plans
11.16 Creative Biogene (U.S.)
11.16.1 Creative Biogene (U.S.) Company Profile
11.16.2 Gammaretroviral Vector Product Overview
11.16.3 Creative Biogene (U.S.) Gammaretroviral Vector Market Performance (2018-2023)
11.16.4 Creative Biogene (U.S.) Business Overview
11.16.5 Recent Developments and Plans
11.17 General Electric (U.S.)
11.17.1 General Electric (U.S.) Company Profile
11.17.2 Gammaretroviral Vector Product Overview
11.17.3 General Electric (U.S.) Gammaretroviral Vector Market Performance (2018-2023)
11.17.4 General Electric (U.S.) Business Overview
11.17.5 Recent Developments and Plans
11.18 Pfizer Inc. (U.S.)
11.18.1 Pfizer Inc. (U.S.) Company Profile
11.18.2 Gammaretroviral Vector Product Overview
11.18.3 Pfizer Inc. (U.S.) Gammaretroviral Vector Market Performance (2018-2023)
11.18.4 Pfizer Inc. (U.S.) Business Overview
11.18.5 Recent Developments and Plans
12 Global Gammaretroviral Vector Forecast Market Analysis by Type
12.1 Global Gammaretroviral Vector Revenue Market Forecast by Type (2023-2029)
13 Global Gammaretroviral Vector Forecast Market Analysis by Application
13.1 Gammaretroviral Vector Revenue Market Forecast by Application (2023-2029)
14 Global Market Growth Forecast Analysis
14.1 Global Gammaretroviral Vector Forecast Market Size (2023-2029)
14.2 Gammaretroviral Vector Growth Trends Forecast Analysis by Regions
14.2.1 Gammaretroviral Vector Revenue Forecast Market Size by Regions (2023-2029)
14.2.2 North America Gammaretroviral Vector Forecast Market Size (2023-2029)
14.2.3 Europe Gammaretroviral Vector Forecast Market Size (2023-2029)
14.2.4 Asia-Pacific Gammaretroviral Vector Forecast Market Size (2023-2029)
14.2.5 Latin America Gammaretroviral Vector Forecast Market Size (2023-2029)
14.2.6 Middle East & Africa Gammaretroviral Vector Forecast Market Size (2023-2029)
15 Gammaretroviral Vector Industry Dynamic Analysis
15.1 Gammaretroviral Vector Market Trends Analysis
15.2 Gammaretroviral Vector Market Drivers Analysis
15.3 Gammaretroviral Vector Market Challenges Analysis
15.4 Gammaretroviral Vector Market Restraints Analysis
List of Tables and Figures
Figure Gammaretroviral Vector Picture
Table Product Definition of Gammaretroviral Vector
Table Economic Analysis of Global Regions
Table Inflation Analysis
Table The Impact of the Russian-Ukrainian War on the Market
Figure 2020 (COVID-19) Impact on Global Economic Growth 2019, 2020, 2021
Figure Population infected by the Covid-19 of Major Countries
Table Global Gammaretroviral Vector Market Size by Type (2018 VS 2023 VS 2029)
Table Global Gammaretroviral Vector Revenue and Market Size by Type (2018-2023)
Table Global Gammaretroviral Vector Revenue and Market Share by Type (2018-2023)
Table Global Gammaretroviral Vector Market Size by Application (2018 VS 2023 VS 2029)
Table Global Gammaretroviral Vector Revenue Market Size by Application (2018-2023)
Table Global Gammaretroviral Vector Revenue Market Share by Application (2018-2023)
Figure Global Gammaretroviral Vector Revenue Market Size (2018-2023)
Table Gammaretroviral Vector Market Size by Regions: 2018 VS 2023 VS 2029
Table Gammaretroviral Vector Historic Revenue Market Size by Regions (2018-2023)
Table Gammaretroviral Vector Historic Revenue Market Share by Regions (2018-2023)
Figure North America Gammaretroviral Vector Market Size (2018-2023)
Figure Europe Gammaretroviral Vector Market Size (2018-2023)
Figure Asia-Pacific Gammaretroviral Vector Market Size (2018-2023)
Figure Latin America Gammaretroviral Vector Market Size (2018-2023)
Figure Middle East & Africa Gammaretroviral Vector Market Size (2018-2023)
Table North America Gammaretroviral Vector Revenue by Countries (2018-2023)
Table North America Gammaretroviral Vector Revenue Market Share by Countries (2018-2023)
Table North America Gammaretroviral Vector Revenue by Types (2018-2023)
Table North America Gammaretroviral Vector Revenue Market Share by Types (2018-2023)
Table North America Gammaretroviral Vector Revenue by Applications (2018-2023)
Table North America Gammaretroviral Vector Revenue Market Share by Applications (2018-2023)
Figure United States Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Canada Gammaretroviral Vector Revenue and Growth (2018-2023)
Table Asia-Pacific Gammaretroviral Vector Revenue by Countries (2018-2023)
Table Asia-Pacific Gammaretroviral Vector Revenue Market Share by Countries (2018-2023)
Table Asia Pacific Gammaretroviral Vector Revenue by Types (2018-2023)
Table Asia Pacific Gammaretroviral Vector Revenue Market Share by Types (2018-2023)
Table Asia Pacific Gammaretroviral Vector Revenue by Applications (2018-2023)
Table Asia Pacific Gammaretroviral Vector Revenue Market Share by Applications (2018-2023)
Figure China Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Japan Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Korea Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Southeast Asia Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure India Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Australia Gammaretroviral Vector Revenue and Growth (2018-2023)
Table Europe Gammaretroviral Vector Revenue by Countries (2018-2023)
Table Europe Gammaretroviral Vector Revenue Market Share by Countries (2018-2023)
Table Europe Gammaretroviral Vector Revenue by Types (2018-2023)
Table Europe Gammaretroviral Vector Revenue Market Share by Types (2018-2023)
Table Europe Gammaretroviral Vector Revenue by Applications (2018-2023)
Table Europe Gammaretroviral Vector Revenue Market Share by Applications (2018-2023)
Figure Germany Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure France Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure UK Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Italy Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Russia Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Spain Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Nordic Gammaretroviral Vector Revenue and Growth (2018-2023)
Table Latin America Gammaretroviral Vector Revenue by Countries (2018-2023)
Table Latin America Gammaretroviral Vector Revenue Market Share by Countries (2018-2023)
Table Latin America Gammaretroviral Vector Revenue by Types (2018-2023)
Table Latin America Gammaretroviral Vector Revenue Market Share by Types (2018-2023)
Table Latin America Gammaretroviral Vector Revenue by Applications (2018-2023)
Table Latin America Gammaretroviral Vector Revenue Market Share by Applications (2018-2023)
Figure Brazil Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Argentina Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Mexico Gammaretroviral Vector Revenue and Growth (2018-2023)
Table Middle East & Africa Gammaretroviral Vector Revenue by Countries (2018-2023)
Table Middle East & Africa Gammaretroviral Vector Revenue Market Share by Countries (2018-2023)
Table Middle East & Africa Gammaretroviral Vector Revenue by Types (2018-2023)
Table Middle East & Africa Gammaretroviral Vector Revenue Market Share by Types (2018-2023)
Table Middle East & Africa Gammaretroviral Vector Revenue by Applications (2018-2023)
Table Middle East & Africa Gammaretroviral Vector Revenue Market Share by Applications (2018-2023)
Figure Egypt Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure South Africa Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure UAE Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Turkey Gammaretroviral Vector Revenue and Growth (2018-2023)
Figure Saudi Arabia Gammaretroviral Vector Revenue and Growth (2018-2023)
Table Global Gammaretroviral Vector Revenue by Players (2018-2023)
Table Global Gammaretroviral Vector Revenue Market Share by Players (2018-2023)
Figure Global Top 3 Companies Revenue Share in 2022
Figure Global Top 6 Companies Revenue Share in 2022
Table Global Gammaretroviral Vector Players Market Concentration Ratio (CR5) (2018-2023)
Table Gammaretroviral Vector Players Head Office, Business Provided
Table Mergers & Acquisitions
Table New Entrants and Expansion Plans
Table Novasep (France) Profile
Table Product Overview
Table Novasep (France) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Novasep (France) Revenue and Growth Rate
Figure Novasep (France) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table MerckKGaA (Germany) Profile
Table Product Overview
Table MerckKGaA (Germany) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure MerckKGaA (Germany) Revenue and Growth Rate
Figure MerckKGaA (Germany) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Charles River Laboratories (U.K.) Profile
Table Product Overview
Table Charles River Laboratories (U.K.) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Charles River Laboratories (U.K.) Revenue and Growth Rate
Figure Charles River Laboratories (U.K.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table uniQure N.V. (Netherlands) Profile
Table Product Overview
Table uniQure N.V. (Netherlands) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure uniQure N.V. (Netherlands) Revenue and Growth Rate
Figure uniQure N.V. (Netherlands) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Waisman Biomanufacturing (U.S.) Profile
Table Product Overview
Table Waisman Biomanufacturing (U.S.) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Waisman Biomanufacturing (U.S.) Revenue and Growth Rate
Figure Waisman Biomanufacturing (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Creative-Biogene (U.S.) Profile
Table Product Overview
Table Creative-Biogene (U.S.) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Creative-Biogene (U.S.) Revenue and Growth Rate
Figure Creative-Biogene (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Aldevron (U.S) Profile
Table Product Overview
Table Aldevron (U.S) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Aldevron (U.S) Revenue and Growth Rate
Figure Aldevron (U.S) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Addgene (U.S.) Profile
Table Product Overview
Table Addgene (U.S.) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Addgene (U.S.) Revenue and Growth Rate
Figure Addgene (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Oxford Biomedica (U.K.) Profile
Table Product Overview
Table Oxford Biomedica (U.K.) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Oxford Biomedica (U.K.) Revenue and Growth Rate
Figure Oxford Biomedica (U.K.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Thermo Fisher Scientific Inc (U.S.) Profile
Table Product Overview
Table Thermo Fisher Scientific Inc (U.S.) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Thermo Fisher Scientific Inc (U.S.) Revenue and Growth Rate
Figure Thermo Fisher Scientific Inc (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Fujifilm Corporation (Japan) Profile
Table Product Overview
Table Fujifilm Corporation (Japan) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Fujifilm Corporation (Japan) Revenue and Growth Rate
Figure Fujifilm Corporation (Japan) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Spark Therapeutics Inc. (U.S.) Profile
Table Product Overview
Table Spark Therapeutics Inc. (U.S.) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Spark Therapeutics Inc. (U.S.) Revenue and Growth Rate
Figure Spark Therapeutics Inc. (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table ABL Inc. (U.S.) Profile
Table Product Overview
Table ABL Inc. (U.S.) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure ABL Inc. (U.S.) Revenue and Growth Rate
Figure ABL Inc. (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Boehringer Ingelheim International GmbH. (Germany) Profile
Table Product Overview
Table Boehringer Ingelheim International GmbH. (Germany) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Boehringer Ingelheim International GmbH. (Germany) Revenue and Growth Rate
Figure Boehringer Ingelheim International GmbH. (Germany) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Brammer Bio (U.S.) Profile
Table Product Overview
Table Brammer Bio (U.S.) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Brammer Bio (U.S.) Revenue and Growth Rate
Figure Brammer Bio (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Creative Biogene (U.S.) Profile
Table Product Overview
Table Creative Biogene (U.S.) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Creative Biogene (U.S.) Revenue and Growth Rate
Figure Creative Biogene (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table General Electric (U.S.) Profile
Table Product Overview
Table General Electric (U.S.) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure General Electric (U.S.) Revenue and Growth Rate
Figure General Electric (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Pfizer Inc. (U.S.) Profile
Table Product Overview
Table Pfizer Inc. (U.S.) Gammaretroviral Vector Revenue, Gross and Gross Margin (2018-2023)
Figure Pfizer Inc. (U.S.) Revenue and Growth Rate
Figure Pfizer Inc. (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Global Gammaretroviral Vector Revenue Market Size Forecast by Type (2023-2029)
Table Global Gammaretroviral Vector Revenue Market Share Forecast by Type (2023-2029)
Table Global Gammaretroviral Vector Revenue Market Size by Application (2023-2029)
Table Global Gammaretroviral Vector Revenue Market Share by Application (2023-2029)
Figure Global Gammaretroviral Vector Revenue Forecast Market Size (2023-2029)
Table Gammaretroviral Vector Revenue Forecast Market Size by Regions (2023-2029)
Table Gammaretroviral Vector Revenue Forecast Market Share by Regions (2023-2029)
Figure North America Gammaretroviral Vector Revenue Forecast Market Size (2023-2029)
Figure Europe Gammaretroviral Vector Revenue Forecast Market Size (2023-2029)
Figure Asia-Pacific Gammaretroviral Vector Revenue Forecast Market Size (2023-2029)
Figure Latin America Gammaretroviral Vector Revenue Forecast Market Size (2023-2029)
Figure Middle East & Africa Gammaretroviral Vector Revenue Forecast Market Size (2023-2029)
Table Market Trends Analysis
Table Market Drivers Analysis
Table Market Challenges Analysis
Table Market Restraints Analysis
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
| Historical Data (2015-2019) |
|
|
| Influencing Factors |
|
|
| Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|